Lataa...
DRES-16. PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOMA MODELS
INTRODUCTION: Mismatch repair (MMR) deficiency through MSH6 inactivation has been identified in approximately 30% of recurrent gliomas. This MMR deficiency represents a key molecular mechanism of acquired resistance to the alkylating chemotherapeutic agent temozolomide (TMZ). In addition, it is know...
Tallennettuna:
| Julkaisussa: | Neuro Oncol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692025/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.274 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|